- Home
- GKOS vs DVAX Comparison
GKOS vs DVAX Comparison
Compare GKOS & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GKOS
- DVAX
- Stock Information
- Founded
- GKOS 1998
- DVAX 1996
- Country
- GKOS United States
- DVAX United States
- Employees
- GKOS N/A
- DVAX N/A
- Industry
- GKOS Medical/Dental Instruments
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- GKOS Health Care
- DVAX Health Care
- Exchange
- GKOS Nasdaq
- DVAX Nasdaq
- Market Cap
- GKOS 5.7B
- DVAX N/A
- IPO Year
- GKOS 2015
- DVAX 2004
- Fundamental
- Price
- GKOS $103.70
- DVAX $10.16
- Analyst Decision
- GKOS Strong Buy
- DVAX Buy
- Analyst Count
- GKOS 13
- DVAX 4
- Target Price
- GKOS $135.15
- DVAX $26.25
- AVG Volume (30 Days)
- GKOS 917.7K
- DVAX 1.8M
- Earning Date
- GKOS 07-30-2025
- DVAX 08-05-2025
- Dividend Yield
- GKOS N/A
- DVAX N/A
- EPS Growth
- GKOS N/A
- DVAX N/A
- EPS
- GKOS N/A
- DVAX N/A
- Revenue
- GKOS $404,523,000.00
- DVAX $294,620,000.00
- Revenue This Year
- GKOS $27.88
- DVAX $21.18
- Revenue Next Year
- GKOS $27.60
- DVAX $16.83
- P/E Ratio
- GKOS N/A
- DVAX N/A
- Revenue Growth
- GKOS 23.92
- DVAX 24.76
- 52 Week Low
- GKOS $77.10
- DVAX $9.22
- 52 Week High
- GKOS $163.71
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- GKOS 61.87
- DVAX 51.68
- Support Level
- GKOS $100.92
- DVAX $9.79
- Resistance Level
- GKOS $104.58
- DVAX $10.38
- Average True Range (ATR)
- GKOS 3.34
- DVAX 0.35
- MACD
- GKOS 0.40
- DVAX 0.03
- Stochastic Oscillator
- GKOS 73.62
- DVAX 49.51
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.